The companies have also agreed to market end-to-end workflow solutions for multiplex assays in the clinical research market.
Under the partnership, Agilent will integrate its Dako Omnis auto-staining instrument with Akoya’s imaging platform, PhenoImager HT, for multiplex chromogenic immunohistochemistry (mIHC) and immunofluorescent (mIF) assays.
This integration will create a single end-to-end commercial workflow that will include reagents, staining, imaging and analysis.
Together Agilent and Akoya will develop chromogenic and immunofluorescent multiplex assays, which will include spatial analysis for companies that develop precision therapeutics for cancer.
The new assays will help researchers and medical professionals meet patient selection requirements for new therapeutics as well as quickly advance their discoveries to clinical testing.
Using multiplex imaging, spatial phenotyping provides the advantages of single-cell analysis while allowing the preservation of the spatial relationships between cells.
Agilent Diagnostic and Genomics Group president Sam Raha said: “We are delighted to be partnering with Akoya to create industry-leading products and services for multiplex chromogenic and immunofluorescence tissue assays.
“This partnership enables an ecosystem that assists the development of novel precision cancer therapeutics and offers a streamlined workflow to our joint customers in the clinical research market to meet the needs of future clinical diagnostics.”
The company stated that the collaboration aims to develop an end-to-end multiplex solution for biomarker clinical research that is enabled by digital pathology and provides capabilities across the pharma value chain.
It will combine Agilent’s pharma partners network, expertise in companion diagnostic and immunohistochemistry (IHC) workflow, and Dako Omnis instrument install base with Akoya’s spatial analysis expertise, Clinical Laboratory Improvement Amendments (CLIA) lab capabilities and imagers install base.
Under a separate agreement, Akoya Biosciences will also be responsible for distributing and reselling Agilent’s Dako Omnis instrument as a part of the multiplex solution.
Akoya Biosciences CEO Brian McKelligon said: “Multiplex tissue analysis has the potential to transform the field of cancer therapeutics and usher in a new era of precision pathology.
“This partnership and the combined strength of both organisations will catalyse the development and deployment of multiplex tissue-based biomarkers for the benefit of our biopharma and CRO partners and, ultimately, patients.”